Stay updated on Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The clinical trial record describes a Phase 2 study of pembrolizumab with chemotherapy for children and young adults with classical Hodgkin lymphoma, including eligibility criteria, treatment plans, and outcome measures. It also provides study status, participating locations, and record history.
    Difference
    100%
    Check dated 2026-11-10T21:21:42.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the study record remains inaccessible behind a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T21:53:05.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    A general NIH banner announces that federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.” The site revision changed from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:13:21.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.0 to v3.7.1, while the page remains a 403 Forbidden error page.
    Difference
    0.2%
    Check dated 2026-10-06T23:11:44.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error with a Home link, replacing the prior study record content. Content referencing Merck-related information and trial details has been removed in this view, resulting in an access-denied presentation rather than the full study record.
    Difference
    20%
    Check dated 2026-09-22T23:11:19.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    End point definitions for EFS and OS were updated to anchor timing to the first dose and specify progression assessment methods; serum TARC biomarker endpoints were removed.
    Difference
    0.4%
    Check dated 2026-09-15T22:10:37.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page.